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Abstract
Induction of a functional subset of HIV-specific CD4
+ T cells that is resistant to HIV infection could enhance immune
protection and decrease the rate of HIV disease progression. CMV-specific CD4
+ T cells, which are less frequently infected
than HIV-specific CD4
+ T cells, are a model for such an effect. To determine the mechanism of this protection, we
compared the functional response of HIV gag-specific and CMV pp65-specific CD4
+ T cells in individuals co-infected with
CMV and HIV. We found that CMV-specific CD4
+ T cells rapidly up-regulated production of MIP-1a and MIP-1b mRNA,
resulting in a rapid increase in production of MIP-1a and MIP-1b after cognate antigen stimulation. Production of
b-chemokines was associated with maturational phenotype and was rarely seen in HIV-specific CD4
+ T cells. To test
whether production of b-chemokines by CD4
+ T cells lowers their susceptibility to HIV infection, we measured cell-
associated Gag DNA to assess the in vivo infection history of CMV-specific CD4
+ T cells. We found that CMV-specific CD4
+ T
cells which produced MIP-1b contained 10 times less Gag DNA than did those which failed to produce MIP-1b.T h e s ed a t a
suggest that CD4
+ T cells which produce MIP-1a and MIP-1b bind these chemokines in an autocrine fashion which
decreases the risk of in vivo HIV infection.
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Introduction
Antigen-specific CD4
+ T cells are thought to play an important
role in control of HIV and CMV infections. Strong CD4
+
proliferative responses to p24 are associated with control of
viremia and maintenance of cytotoxic T-lymphocytes (CTL) in
HIV-infection [1,2]. Plasma HIV load is inversely correlated with
the frequency of p24-specific IL-2 secreting CD4
+ T cells [3]. Data
from transplant studies suggest that CMV-specific CD4
+ T cells
are required to maintain CMV-specific CD8
+ T cells [4]. The
development of CMV disease in HIV infected individuals is
associated with the loss of CMV-specific CD4
+ T cells [5–7].
Recovery of effective CMV immunity after initiation of highly
active antiretroviral therapy also appears to occur concurrently
with recovery of CMV-specific CD4
+ T cells [7,8].
While HIV-specific CD4
+ T cells are preferentially infected and
depleted by HIV, CMV-specific CD4
+ T cells are often easily
identifiable even in late stage HIV [9–11] and evidence of CMV
disease does not occur until endstage AIDS when CD4
+ T cells
counts are ,100 and more often ,50 cell/ml [12,13]. This
suggests that CMV-specific CD4
+ T cells may produce factors that
protect them from HIV infection in vivo. Delineating these factors
may provide clues as to the types of HIV-specific CD4
+ T cells one
would hope to engender with an effective HIV vaccine.
CMV-specific CD4+ T cells rapidly produce MIP-1b when
stimulated by their cognate antigen [14]. Binding of MIP-1b or the
related chemokines MIP-1a and RANTES can protect CD4
+ T
cells from infection by CCR5-tropic (R5) HIV [15–17]. MIP-1a,
MIP-1b and RANTES all bind human CCR5 at sub-nanomolar
levels [18]. Binding of these ligands to CCR5 could protect against
HIV infections by two mechanisms: i) blocking of the receptor
binding site for HIV, and ii) downregulating surface expression
of CCR5 [19]. Although protection of CD4
+ T cells from
HIV-infection in vitro has been shown by the exogenous addition
of MIP-1a, MIP-1b and RANTES to CD4
+ T cells in culture
[20–22], by the production of MIP-1a, MIP-1b and RANTES by
CD8
+ T cells cultured with CD4+ T cells [21,23,24], and by the
production of MIP-1a, MIP-1b and RANTES by CD4
+ T cells
themselves [25,26], little direct evidence exists showing that
production of these chemokines actually protect CD4
+ T cells
from infection in vivo.
Here we assess the production of cytokines, chemokines, and
their respective mRNAs by CMV-specific CD4
+ T cells. We use
cell-associated Gag DNA to assess the HIV infection history of
comparable antigen-specific CD4
+ T cells which either do or do
not produce MIP-1b. Our data demonstrate that b-chemokine
production by antigen-specific CD4
+ T cells is associated with a
ten-fold reduction in HIV infection in vivo.
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CMV-specific CD4
+ T cells are more polyfunctional than
HIV-specific CD4
+ T cells
We identified six individuals, not on antiretroviral therapy, with
comparable magnitude of antigen-specific responses to overlap-
ping CMV pp65 and HIV gag peptides (Table 1). The median
CMV response was 0.87% (range 0.15–2.38%) and the median
HIV response was 0.52% (0.24–1.61%). Although the frequencies
of HIV-specific CD4
+ T cells and CMV-specific CD4
+ T cells
were not significantly different in these individuals, their patterns
of response were markedly different (Figure 1A). Of the five
functions measured, (production of IFNc, IL-2, MIP-1b and
TNFa, and a marker of degranulation, surface mobilization of
CD107a), the average HIV-specific T cell exhibited 2.1 (1.8–2.6)
different functions whereas the average CMV-specific T cell was
more polyfunctional exhibiting 3.4 (2.9–3.6) different functions
(P,0.05). Production of IFNc, MIP-1b, TNFa and mobilization
of CD107a was the most common functional combination
observed in CMV-specific CD4
+ T cells, comprising a median
of 47% (22–62%) of CMV-specific cells. This functional
combination comprised only 2% (1–19%) of the total HIV-specific
response (Figure 1B). Instead, CD4
+ T cells producing only IL-2
and TNFa, IFNc and TNFa, or TNFa alone made up most of the
total HIV-specific response. The median percentages of CMV-
specific CD4
+ T cells producing IFNc (98%), TNFa (88%), and
IL-2 (27%), were similar to or marginally higher than, the median
percentages of HIV-specific CD4
+ T cells producing these
cytokines (85%, 64%, and 29% respectively). The main functional
difference between HIV- and CMV-specific CD4
+ T cells was
defined by production of MIP-1b and mobilization of CD107a;
the median percentages of CMV-specific CD4
+ T which
mobilized CD107a (58%) and produced MIP-1b (63%) were
much greater than in HIV-specific CD4
+ T cells (28% and 12%,
respectively, P#0.05).
Although the median polyfunctionality of CMV-specific CD4
+
T cells was greater than that found in HIV-specific CD4
+ T cells,
the hierarchy of the functional responses were similar for CD4
+ T
cells with similar levels of polyfunctionality (Figure 1B). For
instance, in both HIV- and CMV-specific CD4
+ T cells, those
which produced only one response usually produced either IFNc
or TNFa. Cells which showed two different functional responses
usually produced either IFNc and TNFa although some cells
produced IL-2 instead of IFNc or TNFa. Cells which produced
three functional responses almost always produced IFNc and
TNFa with either IL-2, MIP-1b or mobilized CD107a in response
to antigenic stimulation. Most cells which produced four different
functional responses lacked only IL-2.
CMV-specific CD4
+ T cells are more mature than
HIV-specific CD4
+ T cells
There are several reports that CMV-specific CD4
+ T cells are
more mature than HIV-specific CD4
+ T cells as defined by
expression pattern of CCR7, CCR5, CD27, CD28 and CD57
[3,9,27,28]. We therefore assessed the proportion of the HIV- and
CMV-specific responses that expressed the surface markers
CD45RO, CD27, and CD57 (Figure 2A and 2B). CMV-specific
CD4
+ T cells were less frequently CD27
+CD45RO
+, median 26%
(6–49%), than HIV-specific CD4
+ T cells, median 58% (13–74%)
(P,0.05). CMV-specific CD4
+ T cells were also more frequently
CD27
2CD57
+, median 42% (8–72%), than HIV-specific CD4
+ T
cells, median 15% (0–50%) (P,0.05).
Unlike HIV-specific CD8
+ T cells in which CD57 positivity was
frequently seen on CD27
+ cells, almost all CD57
+ CMV positive
CD4
+ T cells were CD27
2 (Figure 2A) suggesting an orderly
maturational pathway with memory CD4
+ T cells first expressing
CD45RO and CD27, then CD45RO alone, and then CD45RO
and CD57. The majority of CMV specific CD4
+ T cells were
CD27
257
+, median 42% (8–72%), followed by CD27
2CD57
2,
median 30% (21–48%) and CD27
+CD45RO
+, median 26%
(6–49%).
The functional pattern of CMV-specific and HIV-specific
CD4
+ T cells changes with maturation
We have previously shown that in HIV-uninfected individuals as
CMV-specific CD4
+ T cells mature their response patterns change
[14]. More mature cells infrequently produced IL-2 yet frequently
mobilized CD107a and produced MIP-1b. To determine if a
similar phenomenon was observed in PBMC from HIV infected
individuals, we assessed the functional properties of CMV-specific
CD4
+ T cells that were at different stages of maturation based upon
expression of CD45RO, CD27, and CD57 in the six HIV infected
individuals shown in Figure 1. In CMV-specific CD4
+ T cells
polyfunctionality increased with maturation (Figure 3A & B). The
median number of different functional responses increased from 2.7
(2.2–3.3) in CD45RO
+CD27
+ CD4
+ T cells, to 3.2 (2.5–3.8) in
CD27
2CD57
2 CD4
+ T cells, to 3.7 (2.5–4.1) in CD27
2CD57
+
CD4
+ T cells (P,0.05).
Production of IFNc,T N F a,a n dM I P - 1 b and mobilization of
CD107a was the most common functional combination among
CMV-specific T cells (Figure 1B). The proportion of CMV-
specific CD4
+ T cells expressing this combination of functions
increased with maturation, representing a median of 4% of the
CD45RO
+CD27
+ subset, 24% of the CD27
2CD57
2 subset, and
54% of the CD27
2CD57
+ subset of responding CD4
+ Tc e l l s
(Figure 3B). A similar pattern was seen for CD4
+ Tc e l l sw h i c h
produced IFNc,T N F a, and MIP-1b in responses to antigenic
stimulation. These data show that CMV-specific CD4
+ Tc e l l s
from HIV infected individuals produce MIP-1b just as fre-
quently as CMV specific CD4
+ T cells from non-HIV infected
individuals [14].
Author Summary
HIV infection results in a significant loss of CD4
+ T cells,
particularly HIV-specific CD4
+ T cells. In contrast to this,
CMV-specific CD4
+ T cells persist in large numbers, even in
individuals with AIDS. We compared the functional profile
of HIV-specific and CMV-specific CD4
+ T cells and found
that unlike HIV-specific CD4
+ T cells, CMV-specific CD4
+ T
cells rapidly produce MIP-1b when stimulated with
cognate antigen. CMV specific CD4
+ T cells also produce
another b chemokine when stimulated with cognate
antigen, MIP-1a. Addition of both of these chemokines
to in vitro incubations protects CD4
+ T cells from HIV
infection. To determine if the production of these two
chemokines could protect the CD4
+ T cells that produce
them in vivo, we analyzed peripheral blood cells from HIV
infected individuals and separated CMV-specific CD4
+ T
cells that produced MIP-1b from CMV-specific CD4
+ T cells
that did not. We found that cells that produced MIP-1b
were less frequently infected with HIV than those that did
not produce MIP-1b. These data, and recent advances in
vaccine design, suggest that it may be possible to design a
vaccine in which vaccine-induced HIV-specific CD4
+ T cells
are less susceptible to infection than those usually
produced during HIV infection.
Protective Effects of b-Chemokine Production
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+ T cells produce both MIP-1a and
MIP-1b
Production of MIP-1b by CMV-specific CD4
+ T cells may
protect these cells from HIV infection. In vitro experiments have
shown that in addition to MIP-1b the b-chemokines RANTES and
MIP-1a can also prevent HIV infection [21,22,29,30]. If the
production of b-chemokines is protective against HIV infection in
vivo, determining which of these chemokines is produced in response
to CMV antigens is important. We therefore stimulated PBMC
from 3 HIV-infected individuals and 3 HIV-uninfected individuals
with pp65 peptides and stained for the production of MIP-1a, MIP-
1b, and RANTES (Figure 4A). Median frequency of pp65 specific
CD4
+ T cells was 1.75 (0.7–12.4)%. No evidence of RANTES
production was found intheseassay.MIP-1a andMIP-1b appeared
to stain similarly with a median of 82 (65–97)% of the MIP
producing CD4
+ T cells co-staining for both chemokines. However,
the interpretation of these data are complicated by 2 factors. We
found that the antibody used to stain MIP-1b cross reacted with the
MIP-1a isoform to some extent, making it difficult to determine the
exact frequency of cells producing this chemokine (data not shown).
It was clear however that staining for MIP-1b identified all MIP-
producing species. For this reason MIP-1b was used for all
subsequent sorting experiments. Secondly, it is possible that
RANTES is stored in CD4
+ T cells in a form which is not
accessible to our antibody staining.
To further assess CMV-induced MIP-1a,M I P - 1 b and possible
RANTES production, we determined relative chemokine-specific
mRNA levels using non-cross reacting primers and probes. To
identify antigen specific CD4
+ T cells we stimulated cells with
antigen and surfaced stained CD4
+ T cells for 2 functional responses
induced by cognate antigen stimulation; surface mobilization of
CD107a and surface expression of CD154, a general marker of
CD4
+ T cell activation expressed on most CMV-specific CD4
+
T cells [31]. Live memory CD4
+ T cells were sorted into
Table 1. Age, Sex, viral load, CD4 count and total Gag and pp65-specific CD4
+ responses of subjects studied.
Subject VL CD4 Age (Sex) Experiment
* Gag
1 response pp65
1 response
H1 250 510 62 (M) A 0.71 1.3
H2 553 656 52 (M) A, 1.61 0.54
H3 215 380 58 (M) A 0.78 1.36
H4 477 421 40 (M) A, 0.23 0.24
H5 776 395 35 (M) A, D, E 0.36 0.15
H6 ,50 347 40 (M) A, D, E 0.79 2.38
H7 188000 603 39 (M) B 1.62
H8 6210 331 48 (M) B 14.1
H9 834 113 45 (F) B, C 0.76
H10 669 133 59 (M) C 1.25
H11 251 257 42 (F) C, D 3.33
H12 35300 145 46 (F) D 0.39
H13 15300 752 29 (M) D, E 0.14
H14 3100 430 23 (M) D, E 0.2
H15 68500 328 35 (M) D, E 8.7
H16 5300 448 46 (M) E 0.12
H17 14500 272 21 (M) E 0.45
H18 4410 685 33 (M) E 1.69
C1 46 (M) B 1.51
C2 52 (M) B 1.91
C3 37 (F) B, C 2.97
C4 44 (M) C 0.89
C5 61 (M) C 2.14
C6 23 (M) D 0.94
C7 51 (M) D 1.2
C8 33 (M) C 0.5
C9 43 (M) D 0.57
C10 25 (M) D 0.29
C11 45 (M) D 0.17
C12 43 (M) D 2.87
*(A) indicates PBMC used for the functional analysis shown in Figure 1, 2, and 3. (B) indicates PBMC used for the determination of the production of MIP-1a, MIP-1b,
RANTES, and IFNc shown in Figure 4A. (C) indicates PBMC used for the determination of relative amounts of MIP-1a, MIP-1b, RANTES, and IFNc mRNA shown in
Figure 4B. (D) indicates PBMC used for the determination of surface CCR5 expression shown in Figure 5. (E) indicates PBMC used for the determination of cell
associated Gag DNA shown in Figure 6.
1Gag and pp65 responses are given as a percent of the total CD4
+ population.
doi:10.1371/journal.ppat.1000646.t001
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+ T cell responses. A) Representative plots showing
functional responses to pp65 15mers overlapping by 11, and gag 15mers overlapping by 11. B) Individual pie charts show the percentage of antigen-
specific CD4
+ T cells which produce 1, 2, 3, 4, or 5 functional responses for gag- and pp65-specific CD4
+ T cells. Three, four, and five functional
responses are highlighted by the black arrows. Polyfunctional responses were significantly more frequent in pp65-specific CD4
+ T cells than in gag-
specific CD4
+ T cells (P,0.05). Frequency of functional species for pp65-specific (red bars) and Gag-specific (blue bars) responses are shown in the bar
graph for each of the 31 functional species. Colored bars show the range for the 2
nd and 3
rd quartiles, medians are denoted by the horizontal bar and
standard deviations are shown by whiskers. Significant differences between the frequencies of different individual gag- and pp65-specific functional
species are indicated by a * (P,0.05).
doi:10.1371/journal.ppat.1000646.g001
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2CD107a
2,C D 1 5 4
+CD107a
2 and CD154
+CD107a
+ pop-
ulations (Figure 4B) and the relative amounts of IFNc,M I P - 1 a,
MIP-1b, and RANTES mRNA compared to the amount of mRNA
produced by the housekeeping gene human glucuronide synthetase
(hGUS). The ratio of the cytokine or chemokine mRNA to hGUS
mRNA in antigen specific cells (CD154
+) was compared to the ratios
determined in the cells which did not respond to antigen
(CD107a
2CD154
2). These ratios were used to assess the relative
amounts of IFNc,M I P - 1 a,M I P - 1 b and RANTES mRNAs
(Figure 4C). Median ratios for IFNc:hGUS, MIP-1a:hGUS , and
MIP-1b:hGUS were significantly higher in pp65-specific cells than
in cells that were not stimulated by pp65 (P,0.05). Unlike IFNc,
both MIP-1a and MIP-1b median chemokine:hGUS mRNA ratios
were also higher in antigen specific CD4
+ Tc e l l s( C D 1 5 4
+)t h a t
expressed CD107a than inthose that did not (P,0.05). The increase
in MIP production in cells that are CD107
+ compared to cells that
are CD107
2 is consistent with the increased frequency of MIP
producing cells in the CD107a
+ population shown in Figure 1B. No
increase in production of RANTES mRNA was observed in pp65
specific CD4+ T cells stimulated with antigen. None-the-less, the
presence of measurable RANTES RNA suggested that RANTES
m a yb ep r o d u c e di nC D 4
+ T cells even in the absence of antigenic
stimulation. To assess this we measured the production of RANTES
in unstimulated memory CD4
+ T cells. We could not consistently
measure RANTES in 6 h incubations, but we could measure
RANTES in 24 h incubations containing 0.7mg monensin/ml
(Figure S1). In much the same way that the frequency of MIP-1b
producing cells were greater in more mature cells, we found that the
frequency of RANTES producing cells were greater in
CD27
2CD57
+ memory CD4
+ T cells than in CD27
2CD57
2
memory CD4
+ Tc e l l s( P,0.05) which were in turn were greater
than in CD27
+ memory CD4
+ Tc e l l s( P,0.05). In matched
incubation, no RANTESwas found incells which produced IFNc in
response to stimulation with SEB. RANTES was still found in
memory CD4
+ T cells which did not produce IFNc but the
frequency of RANTES producing cells was less than was found in
incubations that did not contain SEB. These data suggest that
RANTES is produced in more mature memory CD4+ T cells and
then released after stimulation.
Surface expression of CCR5 was lower in MIP-1b
producing than non- MIP-1b producing CMV-specific
CD4
+ T cells
In addition to MIP-1a and MIP-1b preventing binding of gp120
to CCR5 by steric hindrance, MIP-1a and MIP-1b can also down-
regulate surface expression of CCR5 [20,32]. To see if surface
expression of CCR5 was down-regulated in MIP-1a and MIP-1b
producing CD4
+ T cells, we compared the frequency of surface
expression of CCR5 on CMV-specific CD4
+ T cells that produced
MIP-1b (which also contained all MIP-1a producing cells) to that
observed on cells which did not produce MIP-1b. We used
production of IFNc as a marker of CMV-specificcells. CD4
+ T cells
which respondedto CMV weredivided into MIP-1b producing and
non-MIP-1b producing cells (Figure 5A). MIP-1b producing CD4
+
T cells had significantly lower CCR5 surface expression than non-
MIP-1b producing cells (P,0.05). Although CD57
2 CD4
+ T cells
could be divided into 2 groups of cell, CCR5
+ and CCR5
2 cells,
expression of CCR5 on CD57
+ cells varied from individual to
individual, with some CD57
+ cells being predominantly CCR5
+,
somebeingCCR5
2andsomeshowingintermediatelevelsofCCR5
surface expression. As a result of this variability we also compared
mean fluorescence of CCR5 staining between CMV-specific cells
which expressed MIP-1b and cells which did not (Figure 5B). Again,
in both HIV infected individuals and non-HIV infected individuals,
CMV-specific cells which expressed MIP-1b showed lower CCR5
MFIs than cells which did not express MIP-1b (P,0.05). To
determine if this decrease in surface CCR5 staining was caused by
in vitro MIP-1a or MIP-1b production in Brefelden A containing
assays we added pre-titered amounts of purified anti-MIP-1a
and MIP-1b to Brefelden A containing assays in which the total
pp65 induced MIP-1b was 1.35 (0.7–11.5)% of the total CD4
+
population. No increase in CCR5 expression was observed with
addition of anti-MIP-1a and MIP-1b blocking antibodies in either
CD57
2 orCD57
+ memory CD4
+T cells(datanotshown).Reversal
of MIP-1a and MIP-1b induced CCR5 down regulation was used
to titer anti-MIP-1a and MIP-1b antibody (Figure S2).
CMV-specific CD4
+ T cells that produce MIP are less
frequently infected with HIV than those that do not
To address whether MIP-1a and MIP-1b production are
protective in vivo we used cell associated gag DNA as a measure of
Figure 2. pp65-specific CD4
+ T cells are more mature than Gag-
specific CD4
+ T cells. A) Gag-specific and pp65-specific CD4
+ T cells,
shown by blue isobars, are overlaid onto 2 dimensional density plots for
total CD4
+ T cells plotted against CD27 and CD45RO or CD27 and CD57
surface expression. B) For each of the 6 individuals characterized gag-
specific CD4
+ T cells had higher CD27 expression and lower CD57
responses than did pp65-specific CD4
+ T cells (P,0.05).
doi:10.1371/journal.ppat.1000646.g002
Protective Effects of b-Chemokine Production
PLoS Pathogens | www.plospathogens.org 5 October 2009 | Volume 5 | Issue 10 | e1000646Figure 3. pp65-specific CD4
+ T cells become more polyfunctional with increasing maturity. A) Representative plots showing sorting of
CD4
+ T cells into CD27
+CD45RO
+, CD27
2CD57
2 and CD27
+CD57
+ populations and their respective staining for TNFa and MIP-1b. The percentage of
CMV-specific CD4
+ T cells which produced both TNFa and MIP-1b increased dramatically with increasing maturation. B) Maturation markedly
increased polyfunctionality of pp65-specific CD4
+ T cells. Percentage of the total response for CD27
+CD45RO
+ (red bars), CD27
2 CD57
2 (blue bars)
and CD27
2CD57
+ (green bars) memory CD4
+ T cells is shown for each of the 31 functional species for each specific maturational subset. Significant
differences in the frequency of functional subsets is shown between CD45RO
+ CD27
+ and CD27
2CD57
2 memory CD4
+ T cells by a * (P,0.05) and for
differences between CD45RO
+ CD27
+ and CD27
2CD57
+ memeory CD4
+ T cells by a { (P,0.05).
doi:10.1371/journal.ppat.1000646.g003
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PLoS Pathogens | www.plospathogens.org 6 October 2009 | Volume 5 | Issue 10 | e1000646Figure 4. Stimulation of pp65-specific CD4+ T cells increased production of stainable IFNc, MIP-1a and MIP-1b and their respective
mRNA, but not RANTES and its mRNA. A) A plot of CD4+ T cells stimulated with overlapping pp65 15mers shows populations of pp65-specific
cells which stain for IFNc vs MIP-1b, IFNc vs RANTES and MIP-1a vs. MIP-1b. Although staining for MIP-1a and MIP-1b were clearly visible, no evidence
of RANTES staining was apparent. B) PBMC were incubated with overlapping pp65 peptides, anti-CD154 PE, anti-CD107a Alexa680 and monensin for
5 hr. Cells were then stained as described in Materials and Methods, and live CD14
2CD19
2CD3
+CD8
2CD4
+ memory cells were sorted into
CD107
2CD154
2, CD107
2CD154
+ and CD107
+CD154
+ populations as shown. C) The relative expression of IFNc mRNA, MIP-1a mRNA, and MIP-1b
mRNA were all increased compared to the constitutively expressed glucuronide synthetase mRNA in pp65-specific cells (P,0.05). Expression of IFNc
mRNA was no higher in pp65-specific cells which surface mobilized CD107a than in cells that did not surface mobilize CD107a. The ratio of MIP-1a
mRNA, and MIP-1b mRNA to hGUS were increased in pp65 specific cells which surface mobilized CD107a compared to those which did not (P,0.05).
RANTES mRNA was decreased in pp65-specific cells. Results from individuals are color coded. HIV-uninfected individuals are represented with circles;
HIV-infected individuals are represented with triangles.
doi:10.1371/journal.ppat.1000646.g004
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+ T cells [10] in CMV-specific
CD4
+ T cells which did, or did not, stain for MIP-1b after
antigenic stimulation. MIP-1b producing CD4
+ T cells occur
more frequently in CD57
+ cells than in CD57
2 memory CD4
+ T
cells [14]. The frequency of HIV infection of CD57
+ memory
CD4
+ T cells has been reported to be approximately 10 fold less
than in CD57
2 memory CD4
+ T cells [33]. To ensure that the
rate of HIV infection of CD57
+ memory CD4
+ T cells did not
interfere with the interpretation of the effect of MIP-1b production
on HIV infection, we also sorted CMV-specific memory CD4
+ T
cells (cells that were CD45RO
+ or CD45RO
2CD27
2) into
populations which did or did not respond to CMV pp65 peptides
based on IFNc production after a six hour incubation. CMV-
specific CD4
+ T cells were then sorted into 3 populations: MIP-1b
producing CD4
+ T cells that were CD57
+, MIP-1b producing
CD4
+ T cells that were CD57
2, and CD4
+ T cells that did not
produce MIP-1b and were CD57
2 (Figure 6A). There were too
few antigen-specific CD57
+ cells that did not produce MIP-1b to
sort. Cells which did not respond to pp65 were sorted into CD57
+
and CD57
2 populations. In all 5 populations the amount of cell
associated gag DNA was determined and then normalized to a per
cell amount based on the quantity of albumin-encoding DNA.
For each individual studied the amount of cell-associated HIV
gag DNA was less in the unstimulated population that was CD57
+
than in the unstimulated CD57
2 population. The median cell-
associated gag DNA in the CD57
+ population was 4 (1.3–26.6)
fold less than in the CD57
2 population (Figure 6B). Plasma viral
load correlated with cell-associated gag DNA in both the CD57
+
(P,0.01, R
2=0.62) and the CD57
2 populations (P,0.01,
R
2=0.67) based on linear regression analysis (Figure 6B).
Within CD57
2 CMV-specific CD4
+ T cells, cell associated gag
DNA was 11 (2.5–333) fold lower in CD4
+ T cells which produced
MIP-1b than in those that did not (P,0.05). While we did not
have adequate numbers of cells to quantify gag DNA from all
donors in all populations, there was a consistent pattern that
among MIP-1b producing cells, expression of CD57 was
associated with even lower frequencies of HIV gag DNA
(Figure 6C).
We also stimulated PBMC from HIV infected individuals with
SEB to determine if CD57
2 memory CD4
+ T cells producing
IFNc and MIP-1b had lower levels of infection than those that
produced IFNc, but no MIP-1b. We did not find a significant
difference between these two populations (Figure S3).
Discussion
In this study we compared the maturation and function of CMV-
and HIV-specific CD4
+ T cells in individuals with similar
frequencies of CMV- and HIV-specific CD4
+ T cells. We show
thefollowing:i)consistent with priorreports,CMV-specificCD4
+T
cells are more frequently CD27
2 and CD57
+ than are HIV-specific
CD4
+ T cells; ii) CMV-specific CD4
+ T cells are more polyfunc-
tional in that they more frequently mobilize CD107a and produce
MIP-1b than do HIV-specific CD4
+ T cells; iii) CMV specific
CD4+ T cells produce two b-chemokines in response to antigenic
stimulation, MIP-1a and MIP-1b; and iv) CMV-specific CD4
+ T
cells that express MIP-1b and are either CD57
+ or CD57
2 are less
frequently infected with HIV in vivo than CMV-specific CD4
+ T
cells which are CD57
2 and do not express MIP-1b.
Our data, which show decreased HIV infection of MIP-1b
producing CMV-specific CD4
+ T cells compared to similar CMV-
specific CD4
+ T cells which do not produce MIP-1b, support a
large body of in vitro data that show protection of CD4
+ T cells
from HIV infection by b-chemokines. Although we only showed a
decreased rate of infection of CMV-specific CD4
+ T cells with
respect to MIP-1b, this finding almost certainly extends to MIP-1a
also. Our data show that most CMV-specific CD4
+ T cells that
produce MIP-1b in response to antigenic stimulation concurrently
produce MIP-1a. Both chemokines down-regulate surface expres-
sion of CCR5 in CD4
+ T cells in vitro. Both chemokines are
protective in vitro. To our knowledge these data are the first to
suggest that autocrine production of MIP-1a and MIP-1b by
antigen-specific CD4
+ T cells is protective against HIV-infection in
vivo. We were unable to show a difference in the HIV infection
history of CD57
2 memory CD4
+ T cells which produced MIP-1b
and IFNc and those which produced IFNc when stimulated with
the superantigen SEB. The significance of this finding is unclear.
Whereas pp65 stimulates cells with similar cytokine profiles,
maturation levels, and histories of exposure to cognate antigen,
SEB stimulates cells with multiple specificities, maturation levels,
and histories of exposure to cognate antigen. This could affect
their in vivo HIV exposure histories. For instance, SEB responsive
cells that produce MIP-1b could have relatively high levels of HIV
Figure 5. MIP-1b producing pp65-specific CD4
+ T cells have
lower surface expression of CCR5. A) pp65-specific CD4
+ T cells
which either produce or do not produce MIP-1b are overlaid onto a 2
dimensional histograph of memory CD4
+ T cells plotted against CD57
and CCR5 surface expression for a representative HIV-uninfected and
HIV-infected individuals. MIP-1b
+ and MIP-1b
2 memory CD4
+ T cells,
shown by blue isobars, are overlayed on 2 dimensional density plots
showing expression of CCR5 and CD57. B) For all seven of the non-HIV
and all seven of the HIV infected individuals, pp65 specific CD4
+ T cells
which produced MIP-1b had lower MFIs for CCR5 surface expression
than cells which did not produce MIP-1b (P,0.05).
doi:10.1371/journal.ppat.1000646.g005
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CMV when the subject was co-infected with HIV, while a MIP-1b
non-producing cell could have virtually no history of HIV
exposure if its specificity was to a pathogen which the subject
had not encountered during the time of HIV infection (ie. a
measles-specific cell).
The mechanism of protection of CMV-specific CD4
+ T cells in
vivo is probably similar to that proposed for the protection of CD4
+
T cells in vitro. The entry of R5-tropic HIV is blocked by MIP-1a
and MIP-1b and production of these chemokines by CMV-specific
CD4
+ T cells results in a concentration gradient with the highest
concentrations of MIP-1a and MIP-1b near the cells which
produce them. This concentration gradient should result in more
frequent occupancy of the HIV CCR5 binding site, and lower
densities of CCR5 on the cell surface because of MIP-1a and MIP-
1b induced down-regulation of surface CCR5 expression [34]
than on similar cells which do not produce MIP-1a and MIP-1b.
The decrease in CCR5 that we show in Figure 5 most likely is an
underestimation of the effects of MIP production on CCR5
expression. Brefeldin A which traps nascent proteins in the
endoplasmic recticulum was used in almost all of the experiments
reported in this manuscript and most likely severly decreased MIP
secretion in these assays. This supposition is supported by data
showing down regulation of CCR5 expression on memory CD4
+
T cells stimulated by anti-CD2, CD3 CD8 activation beads in the
absence of Brefeldin A; the reversal of this affect by anti-MIP-1a
Figure 6. MIP-1b producing pp65-specific CD4
+ T cells have a lower frequency of HIV infection than do non-MIP-1b producing pp65
specific CD4
+ T cells. A) PBMC were incubated in the presence of BFA and pp65 15mers overlapping by 11 for six hours. pp65-specific CD4
+ T cells
were separated from memory CD4
+ T cells based on production of IFNc. Cells which were non-pp65 specific were sorted into CD57
+ and CD57
2
populations. Cells which were pp65-specific were sorted in MIP-1b
+CD57
+, MIP-1b
+ CD57
2, or MIP-1b
2CD57
2 populations. Quantitative real time PCR
was done on each of these populations to determine the frequency of cell associated gag DNA. B) In all 12 individuals studied, CD57
+ non-pp65
specific cells (open circles) had lower frequencies of cell associated gag DNA than did CD57
2 non-pp65-specific cells (solid triangles) (P,0.01). For
both CD57
+ and CD57
2 CD4
+ T cells log plasma viral load was linearly related to log cell associated gag DNA (P,0.01). R
2 values were 0.62 for CD57
+
cells and 0.67 for CD57
2 cells. C) A plot of the log of cell-associated gag DNA in pp65-specific and non-specific CD4
+ T cells from 8 HIV-infected
individuals. Non-pp65-specific CD4
+ T cells that were CD57
+ had lower amount of cell associated Gag DNA than did non-pp65 CD57
2 CD4
+ T cells
(P,0.01). CD57
2 CD4
+ T cells which were pp65-specific and produced MIP-1b had lower amounts of cell associated Gag DNA than did similar pp65-
specific CD4
+ T cells that did not produce MIP-1b (P,0.05). Where values are not shown, the amount of cell associated gag DNA was below the
detection limit of the method.
doi:10.1371/journal.ppat.1000646.g006
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increase CCR5 expression on activated cells in the presence of
Brefelden A. It therefore seems likely that the affect of MIP-1a and
MIP-1b produced during the course of BFA containing incuba-
tions on CCR5 expression was minimized. The role of RANTES
production in the downregulation of CCR5 and the protection of
CD4
+ T cells is unclear. Our data does not show an increase in
RANTES mRNA production with short term stimulation but does
show constitutive synthesis of RANTES in unactivated memory
CD4
+ T cells in short term ex vivo culture, particularly in cell which
are either CD27
2 or CD27
2CD57
+. The absence of RANTES
staining in SEB stimulated cells which produce IFNc suggest that
RANTES is released from CD27
2 and CD27
2CD57
+ memory
CD4
+ T cells when they are activated.
CMV-specific CD4
+ T cell responses are highly polyfunctional
and have decreased surface expression of CD27 and variable
surface expression of CD57 (Figure 3B). In contrast, HIV-specific
CD4
+ T cells had high levels of surface expression of CD27 and
relatively low levels of CD57 expression compared to CMV-
specific CD4
+ T cells. Although the frequency of IFNc, TNFa and
IL-2 production were similar in both sets of cells, most HIV-
specific cells rarely showed evidence of degranulation or MIP-1b
production. In the individuals we studied there was an exception
to this generalization. In the subject with the highest frequency of
gag-specific CD4
+ T cells, those cells were functionally and
maturationally reminiscent of CMV-specific CD4
+ T cells. They
had lower surface expression of CD27 (11%) and greater surface
expression of CD57 (50%). This individual also had the highest
frequency of CD107a surface mobilization (29%) and MIP-1b
production (61%) in response to stimulation with HIV gag
peptides of the six individuals we studied. The HIV-specific
response we observed in this individual was due to CD4
+ T cell
clones that recognized 3 specific peptide epitopes: p1731–46,
YKLKHIVWASRELER; p2418–33, PRTLNAWVKVVEEKA;
and p24133–148, WIILGLNKIVRMYSP (data not shown). All
three peptides were of similar response frequency and correspond-
ed with regions previously reported as class II epitopes [35]. These
data show that more mature HIV-specific CD4
+ T cells producing
higher amounts of IFNc, TNFa and MIP-1b can be generated
and maintained in HIV infection.
These studies demonstrate that not only do CMV-specific CD4
+
T cells differ in their maturational and functional profile from
HIV-specific CD4
+ T cells, but those specific functions are
associated with protection against infection in vivo. Specifically,
autocrine production of the chemokines MIP-1a and MIP-1b
appears to be the predominant mechanism involved in protection
against in vivo infection of CMV-specific CD4
+ T cells. Induction
of a functional profile in HIV-specific CD4
+ T cells similar to that
seen in CMV-specific CD4
+ T cells could result in a more effective
and durable immune response during HIV infection. Our data
showing decreased rates of HIV infection in MIP-1b producing
CD4
+ T cells and the data of others showing increased cytokine
production in more polyfunctional antigen-specific CD4
+ T cells
[36] suggest that inducing polyfunctional CD4
+ T cells which
produce MIP-1a and MIP-1b could be important for both
therapeutic and preventative HIV vaccines. While the identifica-
tion of a functional profile within CD4
+ T cells that is relatively
protective against HIV infection in vivo is enlightening, the ultimate
goal is to find ways of inducing such polyfunctional CD4
+ T cells
through vaccination, potentially providing the immune system
with cells that had strong effector and helper functions against
HIV, and were simultaneously relatively protected against
infection and deletion by HIV. Recent discoveries into how to
induce polyfunctional CD4
+ T cells through vaccination offer
hope that the practical application of these findings is on the near
horizon [36–39].
Materials and Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. This study was approved by the
Institution Review Board of the NIAID and the Whitman Walker
Clinic. All patients provided written informed consent for the
collection of samples and subsequent analysis.
Subjects
Peripheral blood mononuclear cells (PBMC) were obtained
from twelve HIV uninfected, CMV seropositive individuals
participating in the NIH research apheresis program. PBMC
were obtained from eighteen HIV infected individuals either
recruited from the Whitman Walker Clinic of Washington D.C. or
through the Vaccine Research Center apheresis protocol.
Informed consent was obtained from all subjects prior to
enrollment into this study (Table 1). In some cases the requirement
for specific experiments determined the patients used. For the
comparisions of gag-specific CD4
+ T cell responses to pp65
specific CD4
+ T cell responses we used PBMC from HIV-infected
individuals with gag- and pp65-specific CD4
+ T cell responses
which were greater than 0.1% of the total CD4
+ population. All of
the individuals which we identified for this cohort had viral loads
of ,1000 (Figure 1–3). For experiments where only pp65 specific
CD4
+ T cells were studied we tried to represent individuals with a
broader range of viral load. Finally large numbers of cells were
required for the determination of cell-associated Gag DNA
content in CD57
2 IFNc
+MIP-1b
+ and CD57
2 IFNc
+MIP-1b
2
CD4
+ T cells. For these experiments we only used samples for
which apheresis samples were available (Figure 6). All experiments
were done using cryopreserved PBMC. PBMC were prepared
within 2 hours of apheresis or blood draw. Plasma HIV load and
CD4
+ T cells counts were determined by a CLIA certified
laboratory.
Cell stimulations
Frozen PBMC were thawed, washed twice with RPMI 1640
supplemented with 10% heat inactivated fetal calf serum, 100 U/ml
penicillin G, 100U/ml streptomycin sulfate, and 1.7mm sodium
glutamine (R-10). Cells were then re-suspended in R-10 containing
10 U/ml DNase I (Roche Diagnostics) and rested for two hours
before being washed with R-10 and used for experiments. All
experiments characterizing the immune response of antigen-specific
CD4
+ T cells were done at 2610
6 PBMC/ml in the presence of
1 mg/mleachofaCD28andaCD49d(BDBioscience),and10mg/ml
brefeldin A (BFA) (Sigma Chemical Company) in the absence or
presence of peptide antigens unless otherwise noted. Cell stimulation
in which surface mobilization of CD107a were measured were done
as above, but in addition a pre-titered amount of aCD107a and
0.7 mg monensin/ml (BD Bioscience) was added [40]. For
determination of RANTES production, only monensin was
addeded. Incubations were 6 h in duration unless otherwise noted.
Since we could only identify maturational phenotypes for antigen-
specific responses by cytokine or chemokine production all
maturational data represent the maturation state of these cells after
a 6h incubation period.
Incubations used for determination of mRNA levels were done
in a different manner. Cells were thawed and rested as described
above, but cell incubations were done in 2 ml volumes of R-10
containing 5610
6 PBMC/ml. Incubations contained 1mg/ml
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incubation period pre-titered amount of CD107a-Alexa680 and
CD154-PE along with 0.7mg monensin/ml were added [31]. Cells
were then incubated for an additional 5 hours before staining.
Anti-CD2, CD3, CD28 activation beads were obtained from
Miltenyi Biotec and were prepared as described by the
manufacturer. Cells were activated by the addition of 0.5 beads/
cell and incubated for 5 h before staining.
Antigens
One hundred and twenty-two 15mers overlapping by 11 amino
acids corresponding to the entire clade B HXBc2/Bal R5 chimeric
HIV gag protein sequence were pooled and dissolved in DMSO.
Gag peptides were obtained from Boston Bioscience and were
greater than 70% pure. One hundred and thirty-eight 15mers
overlapping by 11 amino acids corresponding to the entire pp65
protein sequence were pooled and dissolved in DMSO. CMV
pp65 peptides were obtained from JPT peptide technology and
were .70% pure. In pooled peptide mixes, each peptide was at a
concentration of 400 mg/ml. Five ml were added for each ml of
assay volume. Final concentration of peptides was 2 mg/ml.
Antibodies
Directly conjugated monoclonal antibodies (mAbs) specific for
the molecules listed were obtained from the following: IL-2-
allophycocyanin (APC), CD3-Cy7APC, IFNc-FITC, TNFa-
Cy7PE,MIP-1b-PE,CD154-PE,RANTES-PEand CCR5-Cy7PE
were from BD Biosciences; CD45RO-TRPE, CD27-Cy5PE were
from Beckman Coulter; CD4-Cy55PE was from Caltag; MIP-1a-
APC was from R&D. The following antibodies were conjugated in
our laboratory according to standard protocols (http://drmr.com/
abcon/index.html): CD107a-Alexa680, CD8-QD705, CD57-
QD565, CD14-Pacific Blue and CD19-Pacific Blue.
Immunofluorescence staining
Stimulated PBMC used for intracellular cytokine staining were
washed and pre-stained for 10 min with a pre-titered amount of
LIVE/DEAD fixable violet dead cell stain (Molecular Probes). In
some incubations cells were also pre-stained with an anti-CCR5
antibody. After preliminary staining, cells were then surface stained
with a mixture of pre-titered amounts of directly conjugated
antibodies to CD27, CD45RO, CD57, CD8, CD19, and CD14
made to a total volume 100ml with Delbecco’s phosphate buffered
saline (PBS). Cells were stained for 30 min at room temperature in
the dark. Cells were then washed and permeabilized using the
cytofix/cytoperm kit (BD Biosciences) according to the manufac-
turer’s instructions. After intracellular staining for CD3, CD4,
IFNc, MIP-1a, MIP-1b, TNFa, RANTES and/or IL-2 cells were
washed one final time and fixed in PBS containing 1%
paraformaldehyde and then stored in a 4uC refrigerator. Flow
cytometric analysis was done within 24 h of staining.
Stimulated cells used for mRNA quantitation were pre-stained
for 10 min with LIVE/DEAD fixable violet dead cell stain
(Invitrogen) and then stained with pre-titered amounts of directly
conjugated antibodies to CD27, CD45RO, CD19, CD14, CD3,
CD8 and CD4 and made to a total volume 100ml with Dulbecco’s
phosphate buffered saline (PBS). Cells were stained for 30 min at
room temperature in the dark, washed once and then flow
cytometric sorting immediately done.
Flow cytometric analysis
Cells were analyzed with a modified LSRII (BD Immunocytometry
Systems) equipped for the detection of 18 fluorescence parameters.
For all 12 color flow analysis between 500,000 and 1,000,000 events
were collected for each sample. Electronic compensation was
conducted with antibody capture beads (BD Biosciences) stained
separately with individual mAbs used in test samples. All analytical
gating was was performed using FlowJo version 8.2 (Tree Star) as
described previously [14]. Although there were variations in gating
based on the population of interest all CD4
+ T cells were identified in
the same manner. Singlet cells were sorted base on Forward Scatter
Height (FSC-H) and Forward Scatter Area (FSC-A). Dead cells, B
cells, and monocytes were excluded by staining with either LIVE/
DEAD fixable violet dead cell stain or CD14 and CD19 staining.
CD3
+,CD8
2 and CD3
+CD4
+ cells were sequentially selected.
Identification of CD107a, IFNc,I L - 2M I P - 1 b and TNFa was done
in either CD3
+CD8
2CD4
+ T cells, or CD3
+CD8
2CD4
+ T cells that
were CD27
+CD45RO
+,C D 2 7
2 57
2 or CD27
2CD57
2 cell
populations. CCR5 gating was done on memory CD3
+CD8
2CD4
+
T cells that either produced, or did not produce MIP-1b.M e m o r y
cells were defined as all CD3
+CD8
2CD4
+ cells that were not
CD27
+CD45RO
2. Graphs were made using Pestle Version 1.5
(provided by M. Roederer, NIH, Bethesda, MD) and Spice Version
4.1 (provided by M. Roederer, NIH, Bethesda, MD).
Cell sorting
Cell sorting for quantitation of cell-associated Gag-DNA was
accomplished using a FACS Aria cell sorter (BDIS) at 70 lb/in
2.
CD19 Cascade Blue, CD14 Cascade Blue, CD45RO TRPE,
CD27 Cy5PE, CD57 QD565, CD8 QD705, CD3 Cy7APC, CD4
Cy55PE, IFNc FITC, MIP-1b and LIVE/DEAD fixable violet
dead cell stain were used to stain cells. Typically at least 50 million
PBMC were sorted for each experiment in which cell associated
gag DNA was determined.
Sorted populations were consistently .98% pure. Immediately
upon completion of cell sorting cells were centrifuged in 1.5 ml
polypropylene conical test tubes, the supernatant removed and
25–100 ml of 10 mM TRIS buffer containing proteinase K added.
Cells were then incubated at 56uC for 1 hour, and then at 90uC for
10 min. Cell debris was removed by centrifuged and samples stored
at 280uC until quantitative real time PCR (qPCR) was performed.
Cell sorting for quantitation of mRNA was accomplished using
a FACS Aria cell sorter (BDIS) at 70 lb/in
2 (Figure 4B). Cells were
sorted in the following manner: Single cells were sorted based on
Forward Scatter Height and Forward Scatter Area. Dead cells, B
cells, and monocytes were excluded by staining with either LIVE/
DEAD fixable violet dead cell stain or CD14 and CD19 staining.
CD3
+ and CD4
+ cells were sequentially selected, then memory
CD4
+ T cells were selected based on CD27 and CD45RO surface
staining. Live antigen-specific memory CD4
+ T cells were sorted
based on surface expression of CD154 and CD107.
qPCR
Quantification of HIV gag DNA in sorted CD4
+ T cells was
performed by quantitative PCR (qPCR) by means of a 59 nuclease
(TaqMan) assay with an ABI7700 system (Perkin Elmer, Norwalk,
CT) as previously described [33,41]. Standards were constructed
for absolute quantification of gag and albumin copy number and
were validated with sequential dilution of 8E5 cell lysates that
contain one copy of gag per cell. Duplicate reactions were run and
template copies calculated using ABI7700 software.
Quantitation of MIP-1a, MIP-1b, IFNc RANTES and hGUS
mRNA
Memory T cell subsets were sorted directly into RNALater
(Ambion) and centrifuged at 10,000g for 5 min. Supernatents were
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(Ambion). mRNA was then purified using the Oligotex mRNA
extraction kits per the manufactures instructions (Qiagen).
Purified mRNA was added directly to the iScript one step
quantitative RT PCR reaction (Bio-RAD) containing either IFNc,
MIP-1a, MIP-1b, RANTES primers and probes or the normalizing
primers and probes for human b-glucuronidase (hGUS). We used
the following oligonucleotide sequences: MIP-1a forward primer,
GACTACTTTGAGACGAGCAGCCA; MIP-1a reverse primer,
GCCGGCTTCGCTTGGT, MIP-1a probe, FAM- TGCTC-
CAAGCCCGGTGTCATCTTC-BHQ1 (Farber,J J.M. personal
communication); MIP-1b forward primer, AGCGCTCTCAGCAC-
CAATG; MIP-1b reverse primer, TTCCTCGCGGTGTAA-
GAAAAG; MIP-1b probe FAM-CTCAGACCCTCCCACCG-
CCTGC-BHQ1 (Farber,J J.M. personal communication); RANTES
forward primer, ACCAGTGGCAAGTGCTCCA; RANTES re-
verse primer, GCACACACTTGGCGGTTCT; RANTES probe,
FAM- CCAGCAGTCGTCTTTGTCACCCGA-BHQ1 (Farber,J
J.M. personal communication); IFNc forward primer, CGAGAT-
GACTTC GAAAAGCTGAC; IFNc reverse primer, GGCGA-
CAGTTCAGCCATCA; IFNc probe, FAM-TTGAATGTC-
CAACGCAAAGCAATACATGA-BHQ1 (Horner, R. M., personal
communication); hGUS forward primer, CTCATTTGGAATTT-
TGCCGATT, hGUS reverse primer, CCGAGTGAAGATC-
CCCTTTTTA; and hGUS probe, TGAACAGTCACCGACGA-
GAGTGCTGG. Expression levels of human IFNc, MIP-1a,
MIP-1b, and RANTES were normalized to hGUS and calculated
based on the DDCT method [42].
Statistics
Comparison between groups was performed using a criterion of
significance of P#0.05. Allstatistical tests were conducted using SPSS
for Windows (SPSS Inc., Chicago, IL) or JMP (SAS, Cary, NC).
Unless specifically noted all values given are medians (range). Pair-
wise comparisons were made using a Wilcoxon signed rank statistic.
Supporting Information
Figure S1 Production of RANTES by CD4
+ T cells increases
with maturation. PBMC from an HIV-uninfected individuals were
incubated for 24 h with and without the presence of 1mg SEB/ml.
All incubations contained 0.7mg monensin/ml. Cells were surface
stained for CD27, CD45RO, CD57, CD14 and CD19 and a live
dead cell dye as described in Materials and Methods. Cells were
then permeabilzed, washed and stained for CD3, CD4, CD8,
IFNc and RANTES. A.) Although we could not routinely identify
RANTES producing cells in unstimulated cells in 6 h incubations,
we could do so in 24 h incubations. Addition of SEB resulted in a
decrease in the amount of RANTES identified in these assays, No
RANTES was found in IFNc producing cells. Numbers in the
bottom portion of the graph represent the percentage of cells
which did, and did not produce RANTES. B.) RANTES
production increased with maturational phenotype with CD27
+
CD4
+ memory cells showing the lowest frequency of RANTES
production, CD27
2CD57
2 CD4
+ memory cells showing an
intermediate level, and CD27
2CD57
+ cells showing the highest
frequency of RANTES producing cells. C.) In a cohort of six HIV-
uninfected individuals the difference in frequency of RANTES
producing cells between CD27
+ and CD27
2CD57
2 memory
CD4
+ T cells and between CD27
2CD57
2 and CD27
2 and
CD57
+ memory CD4
+ T cells was significantly different at a level
of P,0.05 as determined by a Wilcoxon sign ranked test.
Found at: doi:10.1371/journal.ppat.1000646.s001 (0.77 MB TIF)
Figure S2 Stimulation of memory CD4
+ T cells by CD2
+,
CD3
+, CD28
+ beads results in preferential stimulation of CD57
+
CD4
+ T cells and MIP induced down regulation of surface CCR5
expression. PBMC from an HIV-uninfected individuals were
stimulated with 0.5 CD2
+, CD3
+, CD28
+ beads/PBMC for
5 hours. PBMC used to characterize the production of IFNc and
MIP-1b were incubated with BFA; those used to characterize
surface expression of CCR5 were not. A.) CD57
2 memory CD4
+
T cells were less activated as judged by expression of IFNc than
were CD57
+ memory CD4
+ T cells. They also produced less MIP-
1b. B.) In CD57
2 memory CD4
+ T cells stimulated with CD2
+,
CD3
+, CD28
+ beads in the absence of BFA surface expression of
CCR5 was decreased compared to that observed in cells that were
not stimulated. C.) Similarly, in CD57
+ memory CD4 T cells
stimutated with CD2
+, CD3
+, CD28
+ beads in the absence of BFA
surface expression of CCR5 was decreased compared to that
observed in cells that were not stimulated. CCR5 down regulation
was more marked in CD57
+ memory CD4
+ T cells than in non-
CD57
2 memory CD4
+ T cells. D.) PBMC were stimulated with
CD2
+, CD3
+, CD28
+ beads in the absence of BFA with either no
anti-MIP-1a or anti-MIP-1b blocking antibody or 2, 5 or 10 mgo f
anti-MIP-1a and anti-MIP-1b/ml. At the conclusion of 5 h
incubations containing CD2
+, CD3
+, CD28
+ beads and no BFA
the frequency of surface expression of CCR5 was greater than in
incubations containing anti-MIP-1a and anti-MIP-1b blocking
antibodies than in matched incubations not containing blocking
antibodies. CCR5 surface expression for both CD57
+ and CD57
2
memory CD4
+ T cells are shown as a function of the amount of
blocking antibodies in each incubation. The solid line and dashed
line represent CCR5 expression of unstimulated CD57
2 and
CD57
+ memory CD4
+ T cells, respectively.
Found at: doi:10.1371/journal.ppat.1000646.s002 (0.67 MB TIF)
Figure S3 SEB stimulated CD57
2 memory CD4
+ T cells that
produce MIP-1b do not contain lower amounts of cell associated
Gag DNA than do no non-MIP-1b producing cells CD57
2
memory CD4
+ T cells. PBMC at a concentration of 3E06 PBMC/
ml were incubated in the presence of BFA and 1mg/ml SEB. At
the end of a 6h incubation period cells were stained and sorted in
the same manner as shown in Figure 6. Unlike CMV-specific
CD4
+ T, no significant difference was observed in cell associated
Gag DNA in IFNc producing CD57
2 cells which produced MIP-
1b and those that did not.
Found at: doi:10.1371/journal.ppat.1000646.s003 (0.10 MB TIF)
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